Chris Kofinis of Park Street Strategies visited CNBC to share his opinion on how Heather Bresch, CEO of Mylan, should handle her recent crisis – the high price increase of Mylan’s EpiPen drug and the pay boost Bresch received in light of it.

Click here to subscribe to our YouTube channel to stay up-to-date with latest news and industry insights.